These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 17142323)
1. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Ryu H; Lee J; Hagerty SW; Soh BY; McAlpin SE; Cormier KA; Smith KM; Ferrante RJ Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19176-81. PubMed ID: 17142323 [TBL] [Abstract][Full Text] [Related]
2. Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. Lee J; Hagerty S; Cormier KA; Kim J; Kung AL; Ferrante RJ; Ryu H Hum Mol Genet; 2008 Jun; 17(12):1774-82. PubMed ID: 18319327 [TBL] [Abstract][Full Text] [Related]
3. mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Wang H; An W; Cao R; Xia L; Erdjument-Bromage H; Chatton B; Tempst P; Roeder RG; Zhang Y Mol Cell; 2003 Aug; 12(2):475-87. PubMed ID: 14536086 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. Ferrante RJ; Ryu H; Kubilus JK; D'Mello S; Sugars KL; Lee J; Lu P; Smith K; Browne S; Beal MF; Kristal BS; Stavrovskaya IG; Hewett S; Rubinsztein DC; Langley B; Ratan RR J Neurosci; 2004 Nov; 24(46):10335-42. PubMed ID: 15548647 [TBL] [Abstract][Full Text] [Related]
5. Histone H3-K9 methyltransferase ESET is essential for early development. Dodge JE; Kang YK; Beppu H; Lei H; Li E Mol Cell Biol; 2004 Mar; 24(6):2478-86. PubMed ID: 14993285 [TBL] [Abstract][Full Text] [Related]
6. Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease. Lee J; Hwang YJ; Kim Y; Lee MY; Hyeon SJ; Lee S; Kim DH; Jang SJ; Im H; Min SJ; Choo H; Pae AN; Kim DJ; Cho KS; Kowall NW; Ryu H Acta Neuropathol; 2017 Nov; 134(5):729-748. PubMed ID: 28593442 [TBL] [Abstract][Full Text] [Related]
7. In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level. Park I; Hwang YJ; Kim T; Viswanath ANI; Londhe AM; Jung SY; Sim KM; Min SJ; Lee JE; Seong J; Kim YK; No KT; Ryu H; Pae AN J Comput Aided Mol Des; 2017 Oct; 31(10):877-889. PubMed ID: 28879500 [TBL] [Abstract][Full Text] [Related]
8. Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Yang L; Xia L; Wu DY; Wang H; Chansky HA; Schubach WH; Hickstein DD; Zhang Y Oncogene; 2002 Jan; 21(1):148-52. PubMed ID: 11791185 [TBL] [Abstract][Full Text] [Related]
9. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Schultz DC; Ayyanathan K; Negorev D; Maul GG; Rauscher FJ Genes Dev; 2002 Apr; 16(8):919-32. PubMed ID: 11959841 [TBL] [Abstract][Full Text] [Related]
11. Genomic structure and expression of the mouse ESET gene encoding an ERG-associated histone methyltransferase with a SET domain. Blackburn ML; Chansky HA; Zielinska-Kwiatkowska A; Matsui Y; Yang L Biochim Biophys Acta; 2003 Oct; 1629(1-3):8-14. PubMed ID: 14522075 [TBL] [Abstract][Full Text] [Related]
12. A jumonji (Jarid2) protein complex represses cyclin D1 expression by methylation of histone H3-K9. Shirato H; Ogawa S; Nakajima K; Inagawa M; Kojima M; Tachibana M; Shinkai Y; Takeuchi T J Biol Chem; 2009 Jan; 284(2):733-9. PubMed ID: 19010785 [TBL] [Abstract][Full Text] [Related]
13. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. Li H; Rauch T; Chen ZX; Szabó PE; Riggs AD; Pfeifer GP J Biol Chem; 2006 Jul; 281(28):19489-500. PubMed ID: 16682412 [TBL] [Abstract][Full Text] [Related]
14. Setdb1-mediated histone H3K9 hypermethylation in neurons worsens the neurological phenotype of Mecp2-deficient mice. Jiang Y; Matevossian A; Guo Y; Akbarian S Neuropharmacology; 2011 Jun; 60(7-8):1088-97. PubMed ID: 20869373 [TBL] [Abstract][Full Text] [Related]
16. An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Yang L; Mei Q; Zielinska-Kwiatkowska A; Matsui Y; Blackburn ML; Benedetti D; Krumm AA; Taborsky GJ; Chansky HA Biochem J; 2003 Feb; 369(Pt 3):651-7. PubMed ID: 12398767 [TBL] [Abstract][Full Text] [Related]
17. Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes. Guiretti D; Sempere A; Lopez-Atalaya JP; Ferrer-Montiel A; Barco A; Valor LM Neurobiol Dis; 2016 May; 89():190-201. PubMed ID: 26851501 [TBL] [Abstract][Full Text] [Related]
18. Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B. Jiang Y; Jakovcevski M; Bharadwaj R; Connor C; Schroeder FA; Lin CL; Straubhaar J; Martin G; Akbarian S J Neurosci; 2010 May; 30(21):7152-67. PubMed ID: 20505083 [TBL] [Abstract][Full Text] [Related]
19. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Sarraf SA; Stancheva I Mol Cell; 2004 Aug; 15(4):595-605. PubMed ID: 15327775 [TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. Ferrante RJ; Kubilus JK; Lee J; Ryu H; Beesen A; Zucker B; Smith K; Kowall NW; Ratan RR; Luthi-Carter R; Hersch SM J Neurosci; 2003 Oct; 23(28):9418-27. PubMed ID: 14561870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]